BSE - Delayed Quote INR

Neuland Laboratories Limited (NEULANDLAB.BO)

12,550.75
+116.05
+(0.93%)
At close: 3:29:46 PM GMT+5:30
Currency in INR All numbers in thousands
Download
Breakdown
TTM
3/31/2024
3/31/2023
3/31/2022
3/31/2021
Total Revenue
14,905,696
15,156,631
11,608,985
9,233,341
9,181,767
Cost of Revenue
7,585,375
7,337,967
6,137,853
5,535,020
5,547,189
Gross Profit
7,320,321
7,818,664
5,471,132
3,698,321
3,634,578
Operating Expense
4,135,543
3,744,842
3,127,718
2,737,418
2,538,244
Operating Income
3,184,778
4,073,822
2,343,414
960,903
1,096,334
Net Non Operating Interest Income Expense
-13,326
-57,706
-115,108
-124,994
-162,308
Pretax Income
3,992,314
4,014,365
2,157,464
821,625
1,053,336
Tax Provision
993,673
1,013,576
522,288
183,405
247,028
Net Income Common Stockholders
2,998,641
3,000,789
1,635,176
638,220
806,307
Diluted NI Available to Com Stockholders
2,998,641
3,000,789
1,635,176
638,220
806,307
Basic EPS
233.72
233.89
127.45
49.74
62.85
Diluted EPS
233.72
233.89
127.45
49.74
62.85
Basic Average Shares
12,830.03
12,829.89
12,829.89
12,829.89
12,829.89
Diluted Average Shares
12,830.03
12,829.89
12,829.89
12,829.89
12,829.89
Rent Expense Supplemental
--
9,202
8,381
7,132
7,142
Total Expenses
11,720,918
11,082,809
9,265,571
8,272,438
8,085,433
Net Income from Continuing & Discontinued Operation
2,998,641
3,000,789
1,635,176
638,220
806,307
Normalized Income
2,999,541.57
3,001,685.27
1,614,498.54
652,264.92
808,399.82
Interest Income
--
82,268
15,563
9,950
16,675
Interest Expense
66,364
110,744
104,015
95,335
128,005
Net Interest Income
-13,326
-57,706
-115,108
-124,994
-162,308
EBIT
4,058,678
4,125,109
2,261,479
916,960
1,181,341
EBITDA
4,709,851
4,722,108
2,789,253
1,407,362
1,578,166
Reconciled Cost of Revenue
7,585,375
7,337,967
6,137,853
5,535,020
5,547,189
Reconciled Depreciation
651,173
596,999
527,774
490,402
396,825
Net Income from Continuing Operation Net Minority Interest
2,998,641
3,000,789
1,635,176
638,220
806,307
Total Unusual Items Excluding Goodwill
-1,199
-1,199
27,282
-18,081
-2,734
Total Unusual Items
-1,199
-1,199
27,282
-18,081
-2,734
Normalized EBITDA
4,711,050
4,723,307
2,761,971
1,425,443
1,580,900
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
-298.43
-302.73
6,604.54
-4,036.08
-641.18
3/31/2021 - 12/18/2000

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

SUVENPHAR.NS Cohance Lifesciences Limited
1,063.30
-1.35%
 
AJANTPHARM.NS Ajanta Pharma Limited
2,482.30
-2.19%
 
PPLPHARMA.NS Piramal Pharma Limited
212.00
+2.04%
 
LAURUSLABS.NS Laurus Labs Limited
593.45
+0.79%
 
RDY Dr. Reddy's Laboratories Limited
13.40
+1.67%
 
ELAN Elanco Animal Health Incorporated
11.96
-2.61%
 
LNTH Lantheus Holdings, Inc.
81.74
+1.62%
 
RGC Regencell Bioscience Holdings Limited
366.01
+72.65%